Session 7 |
Vision Valorisation | sold out
14.00 - 15.30 hrs
Innovation out of academia, whether it leads to a new company or is embedded in a PPP, always starts by translating a research idea into a potentially new product, technology or service. Our academic life sciences are among the world’s best, but we could or should be doing better in capitalising on this excellent knowledge base.
In this session, we will propose measures to remove the barriers in the value creation chain. We will discuss how to empower universities to transform knowledge transfer into a true commitment and to motivate and reward academic researchers to participate actively in valorising their findings. We will address structural and long-term policies to be taken by our government to pave the road from academia
to market. We will identify regulatory barriers that hamper the approval and uptake of new healthcare and agricultural products.
In short, we will discuss how to really turn life sciences into one of our country’s lifelines.
Turning Life Sciences into our Country's Lifeline
|
Chair & introduction
Koen Wiedhaup, BioGeneration Ventures
BioPartner Program: long term outcome
Maarten van Dongen, Managing Partner InnoTact Consulting
Valorisation in the Netherlands: status quo and future
Chrétien Herben, manager valorisation, NGI
Indian summer for Agro Biotechnology: beyond the current EU regulation
Arjen van Tunen, CEO Keygene
Developing biotech medicines in the Netherlands, hinderances, issues and solutions
Rein Strijker, CEO, DNage/Pharming
Back to Parallel Sessions
